[2-(3,4-dichlorophenoxy)-5-(5-methylthiophen-2-yl)benzyl]-methylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [2-(3,4-dichlorophenoxy)-5-(5-methylthiophen-2-yl)benzyl]-methylamine
• 英文别名: 1-[2-(3,4-dichlorophenoxy)-5-(5-methylthiophen-2-yl)phenyl]-N-methylmethanamine
• 化学式: C₁₉H₁₇Cl₂NOS
• 分子量: 378.322
• InChiKey: WKOZOESISFTQMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  49.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Combination treatment for alcoholism and alcohol dependence
  申请人：Pfizer Inc.

  公开号：US20030130322A1

  公开（公告）日：2003-07-10

  The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.

  本发明涉及一种治疗哺乳动物（包括人类）酗酒或酒精依赖的方法，该方法包括给哺乳动物以单胺再摄取抑制剂与阿片受体拮抗剂的组合。本发明还涉及含有药学上可接受的载体、单胺再摄取抑制剂和阿片受体拮抗剂的制药组合物。
• Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
  申请人：Pfizer Inc.

  公开号：US20030055038A1

  公开（公告）日：2003-03-20

  The present invention relates to compounds of formula I, 1 and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.

  本发明涉及I式化合物及其药学上可接受的盐。I式化合物表现出作为血清素、去甲肾上腺素和多巴胺的再摄取抑制剂的活性，并可用于治疗中枢神经系统和其他疾病。
• Combination treatment for depression and anxiety
  申请人：Pfizer Products Inc.

  公开号：EP1260221A2

  公开（公告）日：2002-11-27

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with a dopamine D3 receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and a dopamine D3 receptor agonist.

  本发明涉及一种治疗哺乳动物（包括人类）抑郁或焦虑的方法，其方法是向哺乳动物施用单胺再摄取抑制剂与多巴胺 D3 受体激动剂。本发明还涉及含有药学上可接受的载体、单胺再摄取抑制剂和多巴胺 D3 受体激动剂的药物组合物。
• Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
  申请人：Pfizer Products Inc.

  公开号：EP1262196A2

  公开（公告）日：2002-12-04

  The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.

  本发明涉及一种治疗哺乳动物（包括人类）酒精中毒或酒精依赖症的方法，其方法是向哺乳动物施用单胺再摄取抑制剂与阿片类拮抗剂。它还涉及含有药学上可接受的载体、单胺再摄取抑制剂和阿片类拮抗剂的药物组合物。
• BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1220831B1

  公开（公告）日：2005-06-08